Search

Author/Creator Pérol, M

1. 28TiPCHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists. (17th December 2018)

Authors:
Penault-Llorca, F; Caux, C; Depil, S; Le Tourneau, C; Pérol, M; Robert, C; Soumelis, V; Couch, D; Isambert, N; Fernandez, Y; Filleron, T; Vassal, G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 79PCell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers. (7th November 2019)

Authors:
Vanacker, H; Cassier, P A; Pérol, M; Saintigny, P; Eberst, L; Carbonnaux, M; Brahmi, M; Verlingue, L; Ray-Coquard, I L; Pérol, D; Blay, J-Y
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 7
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 90PReal-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database. (13th April 2019)

Authors:
Girard, N; Pérol, M; Simon, G; Audigier Valette, C; Gervais, R; Debieuvre, D; Schott, R; Quantin, X; Coudert, B; Lena, H; Carton, M; Robain, M; Filleron, T; Chouaid, C
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. (12th September 2018)

Authors:
Gadgeel, S; Peters, S; Mok, T; Shaw, A T; Kim, D W; Ou, S I; Pérol, M; Wrona, A; Novello, S; Rosell, R; Zeaiter, A; Liu, T; Nüesch, E; Balas, B; Camidge, D R
Journal:
Annals of oncology
Issue:
Volume 29:Number 11(2018)
Page Start:
2214
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. (4th October 2019)

Authors:
Moro-Sibilot, D; Cozic, N; Pérol, M; Mazières, J; Otto, J; Souquet, P J; Bahleda, R; Wislez, M; Zalcman, G; Guibert, S D; Barlési, F; Mennecier, B; Monnet, I; Sabatier, R; Bota, S; Dubos, C; Verriele, V; Haddad, V; Ferretti, G; Cortot, A
Journal:
Annals of oncology
Issue:
Volume 30:Number 12(2019)
Page Start:
1985
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. (13th March 2019)

Authors:
Trédan, O; Wang, Q; Pissaloux, D; Cassier, P; de la Fouchardière, A; Fayette, J; Desseigne, F; Ray-Coquard, I; de la Fouchardière, C; Frappaz, D; Heudel, P -E; Bonneville-Levard, A; Fléchon, A; Sarabi, M; Guibert, P; Bachelot, T; Pérol, M; You, B; Bonnin, N; Collard, O
Journal:
Annals of oncology
Issue:
Volume 30:Number 5(2019)
Page Start:
757
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. (14th June 2018)

Authors:
Bonomi, P D; Gandara, D; Hirsch, F R; Kerr, K M; Obasaju, C; Paz-Ares, L; Bellomo, C; Bradley, J D; Bunn Jr, P A; Culligan, M; Jett, J R; Kim, E S; Langer, C J; Natale, R B; Novello, S; Pérol, M; Ramalingam, S S; Reck, M; Reynolds, C H; Smit, E F
Journal:
Annals of oncology
Issue:
Volume 29:Number 8(2018)
Page Start:
1701
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗